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Abstract
Tricuspid regurgitation (TR) usually develops secondarily to left-sided heart diseases, whereas
primary lesions to the valve apparatus is less common. Untreated severe TR has a poor 
prognosis and surgical treatment, i.e., valve repair or replacement, is the only treatment option
with class I recommendation. However, cardiac surgical procedures may be associated with a 
high risk of complications. Recent advances in percutaneous approaches to managing 
structural heart diseases, especially mitral valve diseases, have enabled the implementation of 
this therapeutic strategy in the population of patients with TR. This paper presents data on the 
clinical efficacy, cost-effectiveness and expected population size for one of these procedures, 
namely the TriClip TTVr System procedure. Its efficacy was assessed in the TRILUMINATE 
study involving 85 patients with co-morbidities and at high surgical risk. After 1 year of 
follow-up, the reduction in the TR grade was reported in 71% of patients. Clinical 
improvement in New York Heart Association functional class, a 6-minute walk test, and the 
quality of life were also observed. A published analysis comparing percutaneous treatment 
modalities with a drug therapy based on data from medical registers was utilized, and 
propensity score matching was also employed. Percutaneous treatment reduced 1-year 
mortality and rehospitalisation risk. The economic analysis showed the use of TriClip TTVr 
System is cost-effective: the cost of an additional quality-adjusted life year ranged from 
approximately PLN 85,000 to PLN 100,000, which is below the official threshold in Poland. 
The potential annual number of candidates for this treatment modality in Poland is estimated 
at 265.
Key words: tricuspid regurgitation, transcatheter tricuspid valve interventions, 
transcatheter tricuspid valve repair, TriClip TTVr System, MitraClip
Introduction
This paper summarises the discussion held at meetings of an advisory board comprised
of experts in interventional cardiology and cardiac surgery. The meetings took place between 
May and September 2020. They were attended by 7 clinicians representing 5 centers 
experienced in treating patients with tricuspid regurgitation. This paper aims to identify a 
potential place for CE-marked TriClip TTVr System (Abbott, USA; Central illustration) in the
treatment of tricuspid regurgitation (TR) in Poland, present clinical evidence of its 
effectiveness, attempt to determine its cost-effectiveness and estimate the number of potential 
Polish patients if the technology was available.
Tricuspid regurgitation: Epidemiology
Tricuspid regurgitation is the most common heart valve pathology. Trace or mild TR is
a common finding, reported in over 70% of the population [1]. In a study published in 2020 
which included more than 33,000 patients referred for echocardiography, mild TR was 
detected in 21.9% of patients, moderate — 8%, while severe — 0.8% [2]. OxVALVE registry 
showed that prevalence of moderate/severe TR in the general population was 2.7% [3].
The incidence of TR increases with age. In a population-based study conducted in 
Olmsted County (USA), moderate or severe TR was detected in 0.05% of patients aged 18–44
years and in 3.96% of patients aged > 75 years [4]. TR was significantly more frequently 
diagnosed in females. Similar relationships were presented in an earlier analysis based on the 
Framingham study: in the 40–49-year age group, at least moderate TR was detected in 0.5% 
of females and 0.3% of males while in the 70–83-year age group — in 5.6% of females and 
1.5% of males [1]. Therefore, it can be assumed that moderate-to-severe TR affects 
approximately 4% of individuals over 75 years of age. Isolated regurgitation was diagnosed in
about 8% of patients, while others had co-existent cardiac and non-cardiac comorbidities.
No reliable data on the incidence of TR in Poland are available. Given the 
epidemiological data for the United States, it is estimated that some level of TR affects 
approximately 200,000 individuals in Poland [5].
Etiology and pathogenesis of tricuspid regurgitation
Most TR cases are secondary to right ventricular (RV) overload and dilation. The most
common mechanism underlying TR development is the dilation of the valve annulus (at the 
site of insertion of the anterior and posterior leaflets) with normal leaflet morphology (type I) 
and/or RV enlargement (which results in papillary muscle displacement with restricted leaflet 
position) — type IIIb. Secondary TR occurs due to left-sided heart diseases (including left 
ventricular [LV] dysfunction and mitral valve disease), other forms of pulmonary 
hypertension, atrial fibrillation, heart tumors or as a result of RV myocardial injury in the 
course of coronary artery disease or cardiomyopathy. 
Injury to valve leaflets or the subvalvular apparatus, which leads to the development of
the much less common primary TR (~15%) [4], may be caused by infective endocarditis 
(especially in cases of intravenous drug abuse), rheumatic heart disease, carcinoid syndrome, 
myxoid degeneration, endomyocardial fibrosis, congenital defects (Ebstein’s anomaly, 
congenital valve dysplasia), chest trauma or the increasingly common iatrogenic injury 
(transvenous electrodes, endomyocardial biopsy, ionizing radiation, drug-induced lesions). 
Tricuspid regurgitation leads to right atrial and RV volume overload; once the 
compensatory capacity of the right heart chambers is exhausted, the patient develops systemic
venous congestion and severe heart failure.  
Clinical presentation and prognosis of patients with TR
Clinical manifestations of this defect depend on the severity of the comorbidities and 
initially tend to be non-specific (fatigue, worsened exercise tolerance, shortness of breath). 
Patients develop peripheral edema, jugular vein dilatation and hepatomegaly. Persistent, 
hemodynamically significant TR results in increased venostasis and edema (despite diuretic 
therapy) as well as hepatic hyperemia, which lead to organ dysfunction and gradual 
development of cardiac cirrhosis. 
The diagnosis of advanced TR worsens the prognosis. A meta-analysis of 70 studies 
involving over 32,500 patients with a mean follow-up of 3.2 ± 2.1 years showed that 
moderate/severe TR was associated with a 2-fold increase in the risk of death compared with 
mild/no regurgitation (relative risk [RR] = 1.95; 95% confidence interval [CI] = 1.75–2.17) 
[6]. The relationship between TR severity and all-cause mortality remained significant also 
after adjustment for pulmonary artery systolic pressure (PASP; meta-analysis of 13 studies; 
RR = 1.85; 95% CI = 1.44–2.39) and RV dysfunction (meta-analysis of 15 studies; RR = 1.78;
95% CI = 1.49–2.13). Moderate/severe TR also increased cardiac mortality (RR = 2.56; 95% 
CI = 1.84–3.55) and heart failure hospitalization rates (RR = 1.73; 95% CI = 1.14–2.62). A 
gradual increase in the risk of all-cause mortality was observed (RR = 1.25; 1.61; and 3.44, 
respectively; p < 0.001 for the trend) in patients with mild, moderate and severe regurgitation 
compared to patients without TR.
The presence of significant TR worsens the prognosis of patients regardless of LV 
function. A large retrospective study (over 5,200 patients, 4-year follow-up) showed that 
moderate or higher-grade TR was associated with increased mortality regardless of PASP 
(hazard ratio [HR] = 1.31; 95% CI = 1.16–1.49 for PASP > 40 mm Hg and HR = 1.32, 95% 
CI = 1.05–1.62 for ≤ 40 mm Hg) and regardless of LV ejection fraction (EF) (HR = 1.49; 95%
CI = 1.34–1.66 for EF < 50% and HR = 1.54; 95% CI = 1.37–1.71 for EF ≥ 50%) [7]. 
Compared with the absence of TR, patients with moderate-to-severe defects had worse 
prognosis also after adjustment for age, systolic function of both ventricles, RV dimension 
and inferior vena cava dilatation (HR 1.17; 95% CI = 0.96–1.42 for moderate regurgitation 
and HR = 1.31; 95% CI = 1.05–1.66 for severe regurgitation).
Diagnostic evaluation
Transthoracic echocardiography (and transesophageal echocardiography in selected 
cases) is the most important diagnostic method in evaluation of TR prior to intervention. It 
requires advanced skills and high-quality equipment utilizing full range of echocardiographic 
techniques, including 3-dimensional (3D) imaging. Echocardiography plays a key role in 
differentiating between primary and secondary valve regurgitation for determining the main 
mechanism and etiology of the defect and assessing its severity. The evaluation should 
involve assessment of the morphology of the valve itself, the size of the right heart chambers 
and tricuspid annulus, dimension and collapsibility of the inferior vena cava and assessment 
of RV systolic function. Doppler analysis of the regurgitation jet and the assessment of the RV
systolic pressure are also crucial elements of comprehensive assessment. Despite the use of 
new echocardiographic techniques (including 3D imaging), valve assessment is challenging in
some patients because of poor echogenicity of leaflets and difficulties in obtaining a good 
acoustic window. Special skills are required to carry out transesophageal assessment because, 
in contrast to mitral valve, tricuspid valve is located distally and non-axially to the 
oesophagus.
Tricuspid regurgitation grading is based on a combined analysis of multiple parameters 
[8]: qualitative, semi-quantitative and quantitative. Qualitative criteria apply to valve 
morphology (leaflet thickening/prolapse/restriction/substantial coaptation defect), 
regurgitation jet assessment in colour Doppler (very large central jet or eccentric jet striking 
the right atrial wall) and assessment of the regurgitation jet by continuous wave Doppler 
signal (dense/triangular with early peaking [peak velocity of < 2.0 m/s in severe TR]). Semi-
quantitative criteria are as follows: 
— regurgitation vena contracta width ≥ 7 mm;
— proximal isovelocity surface area radius ≥ 9 mm at Nyquist cutoff value of 0.3 m/s;
— hepatic veins systolic flow reversal;
— tricuspid inflow pattern with E wave dominance ≥ 1.0 m/s. 
Echocardiographic quantitative criteria for severe TR include: 
— effective regurgitant orifice area (EROA) ≥ 40 mm2;
— regurgitation jet volume ≥ 45 mL;
— enlargement of the right heart chambers, and dilatation of the inferior vena cava. 
It should be noted that so far, no cut-off points for moderate and mild regurgitation 
have been established for quantitative parameters of TR (EROA, regurgitation jet volume). 
However, as demonstrated by clinical studies of new percutaneous valve repair techniques, 
severe TR affects patients with very advanced defects and regurgitation jet quantitative 
parameters significantly above the cutoffs proposed. To allow for precise grading of TR in this
group of patients in the context of enrolment for percutaneous interventions and their outcome
monitoring, Hahn and Zamorano [9] presented a new, 5-grade classification of TR. They 
proposed additional massive regurgitation and torrential regurgitation based on the assessment
of vena contracta (14–20 mm for massive regurgitation and ≥ 21 mm for torrential 
regurgitation) and EROA (60–79 mm2 for massive regurgitation and ≥ 80 mm2 for torrential 
regurgitation). Furthermore, they introduced another echocardiographic assessment criterion, 
namely 3D vena contracta area with the cutoffs of 75–94 mm2 for severe regurgitation, 95–
114 mm2 for massive regurgitation, and ≥ 115 mm2 for torrential regurgitation. This expanded 
TR classification also has a prognostic value, because the outcomes of patients with massive 
and torrential TR have incremental risk of mortality in comparison to severe TR.  
In turn, Dreyfus et al. [10] proposed classification of functional TR and qualification 
for surgical treatment based not on regurgitation jet assessment alone but also on the tricuspid 
annular size (diastolic diameter of > 40 mm is considered a significant dilatation) and 
tricuspid leaflet coaptation (normal/leaflet restriction/no coaptation).
Current recommendations of scientific societies on the management and treatment of 
TR
Tricuspid regurgitation is a major challenge not only in terms of diagnostics but 
primarily in terms of treatment. Currently, surgical treatment is the standard of care in severe 
symptomatic isolated valve regurgitation. In the presence of other left-sided valve defects 
requiring surgery, indications for tricuspid valve repair include severe TR or moderate TR 
with coexistent tricuspid annular dilatation. 
Several valve repair techniques have been proposed for cardiac surgery for TR [11]. 
The first method, introduced by Kay, involves posterior leaflet plication, which leads to the 
formation of the bicuspid tricuspid valve. Subsequently, de Vega introduced tricuspid valve 
annuloplasty with suture placement in the posterior and anterior part of the annulus 
(bypassing atrioventricular node). Another modification of surgery was annuloplasty using a 
synthetic ring that restores the normal shape of the valve. Insertion of a semi-open rigid ring is
currently the most widely used method of surgical tricuspid valve repair. 
In cases of RV enlargement and remodeling with leaflet restriction, annular reduction 
as the only treatment option may not be effective enough. In such a situation, anterior 
tricuspid leaflet extension or the clover technique is applied, i.e., suturing valve leaflet edges 
(similar to the Alfieri technique for mitral valve).  
In severe leaflet restriction or organic lesions preventing effective repair, artificial 
(mechanical or biological) valve implantation is necessary. Biological valves are preferred 
due to a lower risk of thrombosis and possibly the chances of subsequent percutaneous 
treatment of its dysfunction (valve-in-valve procedure).
According to the 2017 guidelines of the European Society of Cardiology (ESC) and 
the European Association for Cardiothoracic Surgery (EACTS) on the treatment of valvular 
heart defects [12], a surgical procedure is indicated (class I) in patients with severe primary or
secondary TR undergoing left heart defect surgery. Surgery should also be considered (class 
IIa recommendation) in patients with moderate primary TR undergoing left heart surgery, as 
well as in patients with mild to moderate secondary valve insufficiency with tricuspid annulus
dilatation (≥ 40 mm or > 21 mm/m2, evaluated using 2D echocardiography) undergoing left 
heart surgery. Surgical treatment may be considered at a time of left heart surgery (class IIb 
recommendation) in patients with a history of right-sided heart failure and mild-to-moderate 
secondary TR, even if the tricuspid valve annulus is not dilated.
Indications for surgical treatment of isolated TR include symptomatic disease with 
severe isolated primary TR without severe RV dysfunction (class I recommendation). Surgery 
should be considered in asymptomatic patients or patients with mild symptoms with severe 
primary TR and progressive RV dilatation or worsening RV function (class IIa). After surgery 
for left heart defects and in the absence of recurrent left valve dysfunction, surgery should be 
considered in patients with severe secondary tricuspid insufficiency who develop symptoms 
or progressive RV dilatation/dysfunction, in the absence of severe RV or LV dysfunction and 
severe pulmonary vascular disease/pulmonary hypertension (class IIa). Both ESC/EACTS 
recommendations on the surgical treatment of TR have the level of evidence C, which means 
that they are based on an agreed expert opinion or data from small retrospective studies or 
registries. 
Similar recommendations on the interventional treatment of TR were provided by the 
American Heart Association/American College of Cardiology (AHA/ACC) in 2020 [13]. The 
recommendations concern valve repair primarily in patients undergoing left heart surgery. As 
for the surgical treatment of symptomatic patients with severe primary TR, a lower class (IIa) 
recommendation was provided compared to the European guidelines. In addition, special 
attention is paid to atrial fibrillation in the USA guidelines as the cause of isolated secondary 
TR resulting primarily from annular dilatation.
Eligibility for surgical treatment should be based on the patient’s clinical status, co-
morbidities, and perioperative risk. The right moment for the surgery of the defect has not 
been determined. Similarly, no optimal drug therapy for TR has been defined. According to 
the AHA’s position statement on the diagnosis and treatment of RV insufficiency of 2018, 
drug therapy for RV insufficiency should be based on diuretics (or renal replacement therapy, 
if increased diuretics doses failed); afterload-reducing agents are also used (vasodilators for 
pulmonary circulation), and in extreme cases, mechanical circulatory support [14]. Late-onset 
symptoms of TR and delayed qualification for surgical treatment of the defect have a negative
impact on treatment outcomes [15]. Early and late outcomes of surgical treatment of TR are 
still unsatisfactory.  
In an analysis of nearly 55,000 tricuspid valve surgeries in the USA between 2000 and 
2010 (in 85.7% of cases, the procedure on tricuspid valve accompanied other procedures, with
88.9% of valve repairs), the perioperative mortality rate was 10.6% in 2000 and 8.2% 10 
years later [16]. Predictors of mortality included: older age, high creatinine level, renal failure 
requiring dialysis prior to surgery, cardiogenic shock, use of intra-aortic counterpulsation or 
inotropic agents, presence of significant peripheral or cerebrovascular disease, mitral stenosis,
myocardial infarction, tricuspid valve replacement, chronic pulmonary disease, diabetes 
mellitus, coronary artery disease, urgent surgery, reoperation, congestive heart failure, and all 
other procedures except for double valve replacement (mitral or aortic).  
More recent data (2007–2017) on the outcomes of surgical treatment of isolated TR 
come from 12 centres in France [17]. Most of the 466 patients who underwent surgery for 
tricuspid valve alone (8% of all TR surgeries) had an advanced disease (47% New York Heart 
Association [NYHA] class II/IV; 57% with symptoms of right-ventricular failure). Of these 
patients, 49% were diagnosed with functional TR (22% after left heart surgery, 27% — 
isolated TR) and 51% had an organic defect (including 31% with infective endocarditis). 
Overall, in-hospital mortality following surgery for isolated TR was 10%, including 16% of 
patients after left heart surgery, 13% of patients with isolated functional TR, 5% of patients 
with infective endocarditis and 8% of patients with organic TR of another aetiology. A 
multivariate analysis showed that independent risk factors for in-hospital mortality were as 
follows: NYHA class III/IV (OR = 2.7; 95% CI = 1.2–6.1; p = 0.01), moderate/severe RV 
dysfunction (OR = 2.6; 95% CI = 1.2–5.8; p = 0.02) and lower prothrombin time (OR = 0.98; 
95% CI = 0.96–0.99; p = 0.008); clinical signs of heart failure fell just short of statistical 
significance (OR = 2.4; 95% CI = 0.9–6.5; p = 0.06). Overall, the 1-year survival rate 
following surgery for isolated TR was 86%, while the 5-year survival rate was 75%. 
Independent predictors of mortality in longer follow-up were as follows: NYHA class III/IV 
(HR = 1.7; 95% CI = 1.1–2.8; p = 0.04), clinical signs of right heart failure (OR = 1.8; 95% 
CI = 1.01–3.3; p < 0.05), and lower prothrombin time (OR 0.98; 95% CI = 0.97–0.99; p = 
0.04).
New methods of percutaneous tricuspid valve repair
Minimally invasive surgical procedures and percutaneous valve repair have recently 
been used to treat valvular heart disease. However, due to technical challenges resulting from 
the tricuspid annulus structure, the tricuspid valve was called a ‘forgotten valve’ in terms of 
the percutaneous treatment of heart defects. Only in recent years have attempts been made at 
the transcatheter treatment of TR, based on percutaneous mitral valve treatment experience 
[18].
Percutaneous treatment modalities for TR are based on: 
1. Reduction in the tricuspid annular dimension (percutaneous annuloplasty): 
a. Cardioband (ValtechCardio) — direct annuloplasty using an anchoring system 
to fix and then reduce the size of an artificial annulus, technique originally 
introduced in the percutaneous treatment of mitral regurgitation,
b. The Trialign system (Mitralign, Inc.) — sutures are placed percutaneously in 
the commissural area; cinching of the sutures results in plication of the 
posterior cusp and bicuspidisation of the valve, 
c. The TriCinch system (4Tech Cardio) — by placing one end of the system in 
the anteroposterior commissure area and the other in the IVC, a change in the 
tricuspid annular geometry is achieved;
2. Improvement of cusp coaptation:
a. The Forma system (Edwards Lifesciences) — a polymer balloon is placed in 
the tricuspid orifice and anchored in the RV apex. The balloon fills up the 
regurgitant orifice, 
b. The MitraClip System (Abbott Vascular) — a system for percutaneous 
treatment of mitral valve regurgitation, based on the Alfieri surgical technique 
(edge-to-edge),
c. The PASCAL system (Edwards Lifesciences) — involving the approximation 
of valve leaflets, used for percutaneous mitral valve repair, 
d. The TriClip TTVr System (Abbott Vascular) — based on the MitraClip System
in which the control and clip delivery system were re-designed for the anatomy
and morphology of the right atrioventricular valve (Fig. 1), soon to be 
complemented by a new generation TriClip G4 TTVr System;
3. Caval valve implantation (CAVI):
a. Sapien XT and Sapien 3 valves (Edwards Lifesciences) implanted into the 
inferior vena cava,
b. The TricValve system (P+F PRODUCTS + FEATURES GMBH) based on the 
implantation of biological valves mounted to nitinol stents into the superior 
and inferior vena cava;
4. Percutaneous tricuspid valve implantation (to replace dysfunctional bioprosthesis 
implanted in the tricuspid orifice):
a. The Melody valve (Medtronic),
b. The NAVIGATE valve (NaviGate Cardiac Structures Inc.),
c. The Sapien valve (Edwards Lifesciences);
5. Transcatheter percutaneous implantation of a dedicated self-expanding valve: 
a. The Evoque valve (Edwards Lifesciences).
The outcomes of percutaneous treatment of TR were analyzed, among others, using 
data from the international TRIVALVE registry. The first data concerned 106 patients with 
severe symptomatic TR undergoing percutaneous interventions at 11 centers in Europe, the 
USA and Canada between January 2014 and December 2016 [19]. The mean patient age was 
76 ± 9 years, 60.4% of patients were females, and the EuroScore (European System for 
Cardiac Operative Risk Evaluation) II score was 7.6 ± 5.7%. In total, 35% of patients had 
undergone left heart valve surgery. RV dysfunction (defined as tricuspid annular plane systolic
excursion < 17 mm) was observed in 56.3% of patients, 95% were in NYHA class III/IV. In 
patients who underwent the intervention, functional regurgitation predominated (95.2%); the 
tricuspid annular diameter was 45.4 ± 11 mm, and pre-intervention PASP was 39.7 ± 13.8 mm
Hg. The MitraClip System was most frequently used (n = 58); other devices used were: 
Trialign (n = 17), TriCinch (n = 15), FORMA (n = 7), Cardioband (n = 5), and venae cavae 
valves (n = 3). Procedure efficacy, defined as successful implantation of the device and TR 
reduction to grade ≤ 2, was observed in 62% of patients. In the 30-day follow-up period, 
overall mortality was 3.7% and the incidence of serious cardiovascular and cerebrovascular 
events was 26%. More than half of the patients (58%) were in NYHA class I/II 30 days after 
the procedure. 
Since most patients with TR underwent the ‘edge-to-edge’ procedure with the use of 
the MitraClip System, the authors of the TRIVALVE registry summarised the procedure 
effectiveness at 1 year of follow-up [20]. The analysis included 249 patients with a mean age 
of 77 ± 9 (EuroScore II mean score: 6.4%). With the use of two clips on average (standard 
deviation [SD] = 1), the procedure was effective in 77% of patients. At 1 year of follow-up, 
sustained improvement in the TR grade was observed in 72% of patients, and 69% of patients 
were in NYHA class I/II. Overall, 1 year mortality was 20%, and the composite endpoint of 
mortality and unscheduled hospitalisations for heart failure was 35%. Predictors of annual 
mortality were as follows: ineffective procedure, worsening of renal function and absence of 
sinus rhythm. 
Data from the Trivalve registry showed that ‘edge-to-edge’ procedures are effective in 
most patients and demonstrated marked clinical improvement in high-risk patients subjected 
to percutaneous TR repair. 
The estimated effectiveness of percutaneous TR treatment using the MitraClip TMVr 
and TriClip TTVr Systems 
A systematic review of primary studies of percutaneous TR repair (regardless of the 
devices used) was conducted. The search strategy allowed for both experimental and 
observational (including non-comparative) studies and was not limited to specific devices 
used for valve repair. The review included PubMed, Embase and Cochrane Library data 
(search cut-off date March 20, 2020).
A total of 58 papers were included in the review-based analysis. One comparative 
study was found in which TTVr was compared with drug therapy [21], and 1 study 
concerning TriClip technology — a prospective TRILUMINATE registry [22]. Both studies 
are discussed below.
Taramasso 2019 study
The study involved 472 patients included in the TriValve registry, from 22 European 
and North American sites, who underwent transcatheter tricuspid valve intervention (TTVI) 
between 2016 and 2018. The control group was comprised of patients from 2 retrospective 
registries, including patients with TR who received drug therapy and were additionally 
included in the analysis.
The study was conducted using propensity score matching — a statistical technique 
aimed at increasing the comparability of two patient groups in non-randomised trials by 
dividing patients into pairs based on an estimation of their similarity in terms of clinical 
parameters, to reduce the impact of potential confounding factors, i.e., factors affecting the 
choice of treatment method and at the same time its outcome, and thereby estimate the causal 
effect of the technology in question [23]. Propensity score matching is widely used in clinical 
analyses in the absence of randomised studies, including studies of cardiac procedures [24–
26].
Propensity score matching yielded 268 patient pairs. The primary endpoint was the 
annual all-cause mortality, heart failure rehospitalisation rate, or the composite endpoint of 
both events. 
After matching, patients in the TTVI group, compared with patients receiving drug 
therapy, had lower 1-year mortality (23 ± 3% vs. 36 ± 3%, p = 0.001), a lower risk of 
rehospitalisation (27 ± 3% vs. 47 ± 3%, p < 0.0001) and a lower risk of the composite 
endpoint (32 ± 4% vs. 49 ± 3%, p = 0.0003). The survival analysis using the Cox model 
showed that TTVI was associated with a reduction in the risk of composite endpoint (HR = 
0.60; 95% CI = 0.46–0.79; p = 0.003), also in the multivariate analysis, after adjustment for 
gender, NYHA class, RV dysfunction, and atrial fibrillation (HR = 0.39; 95% CI = 0.26–0.59; 
p < 0.0001), and after adjustment for mitral regurgitation grade and the presence of a 
stimulator/cardioverter defibrillator (HR = 0.35; 95% CI = 0.23–0.54; p < 0.0001).
Improved survival was also confirmed in a subset of patients without concomitant left-
sided valve defects. The type of valve repair device used (MitraClip vs other repair systems) 
did not affect the primary endpoint rate, with MitraClip being the most frequently used device
(229 out of 268 patients).
The obvious limitation of the study, in terms of the aim of this paper, is the use of 
MitraClip rather than TriClip. However, both technologies are based on Alfieri’s (edge-to-
edge) technique with the identical implants which remains after procedure. Differences 
between the technologies result from the clip Delivery System and Steering Guide Catheter, 
reflecting the anatomic challenges of the right side of the heart. Therefore, both technologies 
can be considered similar enough to allow for the use of the data. 
TRILUMINATE study
The TRILUMINATE study aimed to assess the safety and efficacy of the TriClip TTVr 
System in the treatment of patients with symptomatic, at least moderate, tricuspid valve 
insufficiency who were receiving drug therapy and for whom TTVr seemed substantiated 
[22]. This was a prospective, single-arm, multicenter (Europe and the USA) study, with the 
following inclusion criteria:
— age ≥ 18 years and ≤ 90 years at enrolment;
— patients treated according to appropriate standards (including optimal drug therapy) prior 
to enrolment;
— with moderate-to-severe TR;
— NYHA class II or higher;
— no indications for left-sided heart surgery or mitral valve repair.
Exclusion criteria included:
— PASP above 60 mmHg as estimated by echocardiography;
— prior tricuspid valve procedure or the presence of a cardiac implantable electronic device 
(e.g., a transvenous stimulation device), which could prevent proper insertion of the TriClip 
TTVr System device.
The TRILUMINATE study involved 85 patients (66% females) with co-morbidities 
and a high surgical risk. The mean patient age was 77.8 ± 7.9 years and the EuroSCORE II 
score was 8.7 ± 10.7%. Most patients were diagnosed with severe TR (84%), less frequently 
organic (12%) or mixed 94%. The most common co-morbidities included: atrial fibrillation 
(92%), hypertension (86%), kidney diseases (46%), diabetes mellitus (22%) and prior 
myocardial infarction (18%). One-third of the patients had undergone mitral valve 
intervention and 75% of the patients had NYHA class III/IV disease. The efficacy of device 
implantation (defined as a reduction in TR by at least one grade on echocardiography before 
discharge) was 91%. After one year of follow-up, the reduction in the TR grade (to moderate 
at most) was reported in 71% of patients [27]. Clinical improvement in NYHA functional 
class, a 6-minute walk test, and the quality of life were observed. Overall, post-procedure 
mortality in 1-year follow-up was 7.1%. Detailed efficacy and safety data for the TriClip 
TTVr System in the subsequent follow-up period are presented in Tables 1 and 2.  
TripClip cost effectiveness
An attempt was made at estimating the cost-effectiveness of the TriClip TTVr System 
compared to drug therapy for TR, i.e., assessing a mean difference (calculated per patient) in 
the cost from the public payer’s perspective and the effect expressed by life years gained 
(LYG) and quality-adjusted life years (QALYs). The analysis used the only comparative study
available (and discussed above) [21], so the target population for the analysis was consistent 
with patient characteristics in the study. A 1-year horizon was used in the study, and the 
estimated Kaplan-Meier curves for survival at 1 year indicated the value of approximately 
77% for TTVI and ~64% for drug therapy. Given the difference in survival, benefits from 
TTVI are also derived in the years following the procedure. To allow for these benefits, the 
survival curves were extrapolated beyond the horizon of the Taramasso 2019 study to 10 
years, using the Weibull model (Fig. 2). 
In the analysis of QALYs, information on NYHA class distribution and Kansas City 
Cardiomyopathy Questionnaire (KCCQ) values at enrolment and at 6 months were used to 
allow for the technology’s impact on health-related quality of life (Table 3). It was assumed 
that the value of these parameters in patients with the TriClip TTVr System implanted would 
correspond to those observed 6 months in the study (1-year data were available for an 
incomplete group of patients). For patients receiving drug therapy, it was assumed that the 
values would remain at the baseline level. Since only patients on optimal drug therapy at 
enrolment were included in the TRILUMINATE study, it seems reasonable to assume that 
NYHA class in the control group should not be subject to significant changes in the short-term
horizon. In the long-term horizon, both NYHA and KCCQ may likely worsen in both groups. 
However, from the point of view of the economic analysis results, an intergroup difference in 
the parameters plays a key role. This paper de facto assumes that the difference is maintained 
in the long-term horizon.
The NYHA and KCCQ values were assigned health-state utilities based on the results 
of a systematic literature review. As for KCCQ, 1 study was found [28], which showed the 
following dependence: utility = 0.44 + 0.0035* KCCQ-OS. As for NYHA, several studies 
were identified and qualified for parameterisation, which reported utility values for patients 
with heart failure in individual NYHA classes [29–34]. Mean utility values for NYHA class I 
and mean decrements for other groups from the publications found were used. Ultimately, the 
following utility values were used: 0.858 for NYHA class I, 0.762 for NYHA class II, 0.646 
for NYHA class III, and 0.459 for NYHA class IV.
In the analysis, it was assumed that the TTVI cost would amount to approximately 
PLN 125,000. The costs of rehospitalisation were also taken into account, required by 26% of 
patients who had received the TriClip TTVr System and 47% of patients on drug therapy, 
according to the 2019 Taramasso study. It was assumed that the cost of rehospitalization 
would equal the weighted average cost of procedure E50: acute or decompensated heart 
failure — treatment at OINK (PLN 17,000; 80% of patients) and procedure E52: advanced 
circulatory failure (PLN 5,987; 20% of patients). The analysis included the additional costs of
drug therapy used in both patient groups, amounting to approximately PLN 100 per year. 
Future costs and effects were discounted at the rates of 5% and 3.5%, respectively, as per 
Polish HTA guidelines.
The incremental cost-effectiveness ratio for the TriClip TTVr System compared to 
drug therapy for TR was PLN 84,109.79/QALY for the analysis based on the NYHA class and
PLN 101,290.90/QALY for the analysis based on KCCQ. In turn, when considering the 
impact on life expectancy only, the obtained coefficient amounted to PLN 86,422.02/LYG. In 
all cases, the incremental cost-effectiveness ratio value was clearly below the cost-
effectiveness threshold defined in Poland, i.e., PLN 155,514/QALY (or PLN/LYG).
Estimation of the size of the population that may benefit from the TriClip TTVr System
As a rule, TriClip TTVr System should be used in patients with TR and a high cardiac 
surgical risk in whom drug therapy fails to provide satisfactory outcomes. In an attempt to 
determine the size and structure of this population, four groups may be distinguished, which 
should constitute the largest part of the target population:
— high surgical risk or inoperable patients with mitral regurgitation and coexistent TR, with 
indications for the repair of both valves;
— patients after mitral valve surgery who developed moderate-to-severe TR;
— patients with severe TR in the course of RV insufficiency after the implantation of an LV 
assist device;
— patients with isolated severe TR who, in the opinion of the Heart Team, are not candidates 
for surgical valve repair/replacement.
The estimation of the size of the first subpopulation was based on determining the 
annual population of candidates for percutaneous mitral regurgitation treatment. Data from 
other countries were used for this purpose, as Poland’s actual number of procedures may not 
include all patients who needed it. By calculating the average number of procedures with 
respect to the number of citizens, the demand for the edge-to-edge procedure in Poland was 
estimated at 778 per year (due to data confidentiality, they were not presented in this paper). 
The estimated proportion of patients with additional TR ranges from 19.4% [35] to 27%. [36] 
The ultimate size of the first subpopulation can be estimated at approximately 180 patients per
year.
According to National Cardiac Surgery Registry data, 896 mitral valve surgeries were 
performed in Poland in 2019. Assuming that TR develops in 5% of patients after mitral valve 
surgery, the size of the second subpopulation can be estimated at 45 per year. According to the
authors' clinical experience, the size of the third subpopulation should be estimated at 
approximately 20 patients per year. Assuming that isolated TR occurs in approximately 8% of 
patients [17], the size of the fourth group was estimated with respect to the size of the first 
three groups, resulting in approximately 20 patients per year.
In total, the number of patients with likely indications for TriClip TTVr System 
implantation is approximately 265 per year. It should be noted that in the first years of the 
system’s availability, the actual number of procedures would most likely be lower and would 
reach the estimated level only after a few years.
Summary
Severe TR leads to heart failure and worsened quality of life and is associated with a 
poor prognosis. Treatment modalities include drug therapy (of limited effectiveness) and 
cardiac surgery, associated with a very high risk, especially in patients in a worse clinical 
condition, with RV dysfunction and co-morbidities. Thanks to the availability of percutaneous
treatment of TR, patients may be offered an effective, non-invasive procedure associated with 
a low risk of complications. The TriClip TTVr System proved safe and effective in the 
TRILUMINATE study. Based on the Taramasso 2019 study, it may be inferred that 
transcatheter edge-to-edge tricuspid valve repair is more effective than drug therapy regarding
its effect on survival and rehospitalizations but this needs to be confirmed in further studies. 
In light of the survival benefit, improved quality of life, and anticipated cost, the TriClip TTVr
System should be considered cost-effective. A subgroup analysis of patients who could benefit
from the technology suggests that the annual number of procedures could be approximately 
265 after a few years.
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Table 1. TriClip TTVr System effectiveness in the TRILUMINATE study.
Endpoint Assessment at 
30 days (n = 85)
Assessment at 6
months (n = 85)
Assessment at 1 
year 
Reduction in TR severity by at least
1 grade within 30 days of the 
procedure
85.5% 87.1% 87%
NYHA class I/II (25.3% at 
baseline)
79.7% 86.3% 80%
Mean vena contracta width of TR 
[cm] (1.7 cm at baseline)
0.99 0.86 n/a
Quality of life endpoints
6MWT [m], mean improvement 
(277.6, SD: 37.1 at baseline)
n/a 54.6 (SD: 111.4) 33.09 (SD: 62.88)
KCCQ, mean improvement vs 
baseline, score
14.2 (SD: 16.7) 18.6 (SD: 21.5) 16.81 (SD: 23.4)
SF-36 (MCS), mean improvement 
(baseline 44.6, SD: 14.0), score
47.6 (SD: 12.3) 50.1 (SD: 10.6) n/a
SF-36 (PCS), mean improvement 
(35.6, SD: 9.6 at baseline), score
39.5 (SD: 10.0) 42.5 (SD: 9.6) n/a
6MWT — a 6-Minute Walk Test; KCCQ — Kansas City Cardiomyopathy Questionnaire; 
MCS — Mental Component Summary; NYHA — New York Heart Association; PCS — 
Physical Component Summary; SF-36 — Short-Form Health Survey; SD — standard 
deviation; TR — tricuspid regurgitation
Table 2. TriClip TTVr System safety in the TRILUMINATE study.
Endpoint Assessment at 
30 days (n = 85)
Assessment at 6
months (n = 85)
Assessment at 1
year (n = 50)
Major adverse event n/a 5 (6%) 3 (6%)
CV mortality 2 (2.4%) 3 (3.6%) 3 (6%)
Myocardial infarction 0 (0%) 1 (1.2%) 0 (0%)
Stroke 0 (0%) 0 (0%) 0 (0%)
De novo kidney failure 1 (1.2%) 1 (1.2%) 0 (0%)
Any CV surgery for device-related AE 0 (0%) 0 (0%) 0 (0%)
Major bleeding 6 (7.3%) 10 (11.9%) 7 (14%)
Pulmonary thromboembolism 0 (0%) 0 (0%) 0 (0%)
Newly diagnosed hepatic failure 0 (0%) 0 (0%) 0 (0%)
Newly diagnosed atrial fibrillation 1 (1.2%) 1 (1.2%) 0 (0%)
All-cause mortality 0 (0%) 4 (4.8%) 5 (10%)
Single device insertion n/a 5 (7.2%) 3 (6%)
Embolization n/a 0 (0%) 0 (0%)
Tricuspid valve stenosis n/a 7 (10.8%) n/a
Tricuspid valve surgery n/a 1 (1.2%) n/a
CV — cardiovascular
Table 3. New York Heart Association (NYHA) class changes in the TRILUMINATE study 
(the difference from baseline was statistically significant for 30-day, 6-month and 12-month 
follow-up, p < 0.0001).
NYHA class Assessment at 
baseline (n = 83)
Assessment at 
30 days (n = 84)
Assessment at 6 
months (n = 73)
Assessment at 1 
year (n = 65)
NYHA I 0% 23% 36% 32%
NYHA II 25% 57% 51% 51%
NYHA III 70% 20% 12% 17%
NYHA IV 5% 0% 1% 0%
Figure 1. TriClip NT-TriClip XT implant.
Figure 2. Survival curves for transcatheter tricuspid valve intervention (TTVI) and drug 
therapy in the 2019 Taramasso study [21], extrapolated using the Weibull model.
Central illustration. TriClip XT Delivery System.
